- The CCP (Chinese Communist Party) virus likely originated in the WIV.
- The virus was likely modified through dangerous gain-of-function research.
- The National Institutes of Health (NIH) and its National Institute of Allergy and Infectious Diseases (NIAID) likely continue to be involved in dangerous research in China.
- The World Health Organization (WHO) didn’t conduct an impartial investigation of the origins of the virus.
- The CCP and its People’s Liberation Army (PLA) have an advanced biological weapons research and development program that may be functioning within or in coordination with the WIV.
The second expert witness testifying was Dr. David Asher, a senior fellow at the Hudson Institute, who, while working under Secretary of State Mike Pompeo, led the State Department’s investigation of the virus’s origins.
Dr. Francis Collins, director of the NIH, and Dr. Anthony Fauci, director of the NIAID, were invited to testify but declined.
“Every scientific test that distinguishes between the zoonotic and lab leak origins gives results that highly favor the lab origin. We have found no credible evidence that favors zoonotic origin,” Muller told the forum, according to the memorandum.
Giroir agreed, saying, “I assess that the most likely origin was an accidental infection of laboratory personnel from the [WIV lab], with secondary transmission to the local population, and subsequent spread to hundreds of millions of people around the world.”
Among the evidence they pointed to in support of their conclusion was that while more than 80,000 samples were taken from more than 200 animal species linked to the Wuhan open-air meat market near the WIV and elsewhere in China, none tested positive for the virus. The only animals not tested were the humanized mice being used at the WIV in gain-of-function experiments, they said.
In addition, the witnesses noted that a study of the earliest known victims of the virus in China hadn’t visited the Wuhan market, and the CCP acknowledged in May 2020 that the market wasn’t the source of the virus jumping from bats to humans, as both the Chinese regime and the WHO had originally claimed.
The witnesses also said the evidence was overwhelming that gain-of-function research was being conducted at the WIV for some time prior to the original outbreak of the virus in China in November 2019. The first confirmed case appeared in the U.S. in January 2020.
Quay told the forum that the virus “has a unique trigger on its surface called a ‘furin cleavage site’ and a unique code for that site, called a ‘CGG-CGG dimer ... in gain-of-function experiments, the WIV ... [has] inserted furin sites into viruses.
“It is the only sure method that always works and makes viruses more infectious. And the CGG-CGG code found in [the virus] is commonly used in the laboratory; you can literally order it on the internet.”
The virus, he added, was “pre-adapted for human-to-human transmission from the first patient. Specifically, the part of the virus that interacts with human cells was 99.5 percent optimized.”
Giror cited a 2015 Nature Medicine publication in which WIV researchers reported “the creation of a new, hybrid bat coronavirus that could bind to and infect human airway cells.”
All of the witnesses noted that NIH and NIAID funding went to the WIV via sub-grants from the New York-based nonprofit EcoHealth Alliance for gain-of-function research prior to and during a three-year moratorium on such activities from 2014 to 2017.
“After 2017, the pause was lifted and replaced with an impartial oversight body, the P3. According to recently released emails, the NIH bypassed the P3 to continue funding gain-of-function research at the WIV,” the memorandum said.
“No coronavirus work has gone through P3 oversight process. In fact, since 2017, not a single grant, for any research, has gone through P3 oversight process,” the memorandum stated.
“It’s unbelievable to me that coronavirus work would not get even into the [P3] process,” Giroir told the forum. “If you look at the abstract from the latest grant that was done to EcoHealth, it talks about using protein sequence data, infectious clone technology ... this is all gain-of-function.”